Evidence-Based Comparison

Mitochondrial Supplements Compared

Popular mitochondrial supplements differ substantially in what they target, how they are absorbed, and what has actually been demonstrated in humans. This guide compares their mechanisms, evidence, safety, formulation, and cost.

Evidence and pricing reviewed agosto 2026

About this guide

Different supplements target different parts of mitochondrial function

“Mitochondrial support” is a broad category. Some ingredients provide nutrients used directly by mitochondrial enzymes. Others are marketed to influence NAD+ metabolism, mitochondrial signaling, mitophagy, fatty-acid transport, redox balance, or rapid ATP regeneration.

These mechanisms are not interchangeable. An ingredient that changes a biomarker does not necessarily improve mitochondrial function, and an ingredient that improves exercise performance may work through energy buffering rather than by creating new mitochondria.

This guide compares the exact ingredients studied, the strength and directness of the human evidence, formulation and absorption, important safety considerations, and approximate monthly cost.

No single supplement has strong human evidence for every aspect of mitochondrial health. The most useful comparison begins with the specific process being targeted and the outcome actually demonstrated.

Evaluating the evidence

Six questions help separate a plausible mechanism from a demonstrated benefit

These questions are applied consistently throughout this guide. They help prevent research on one chemical form, dose, population, or laboratory marker from being generalized beyond what the evidence supports.

01 · Identity

What exact ingredient and form were studied?

Purified compounds, plant extracts, stereoisomers, salts, and combination formulas may behave differently. Research on cocoa, for example, is not automatically evidence for purified (−)-epicatechin.

02 · Dose

Does the product dose match the research?

A product may contain the right ingredient but provide much less than the amount used in human studies. Dose differences can affect both the relevance of the evidence and the true monthly cost.

03 · Directness

Was mitochondrial function measured directly?

Direct measures may include respiration, ATP production, ATPmax, mitochondrial enzyme activity, muscle-biopsy findings, mitochondrial content, or quality-control processes such as mitophagy.

04 · Relevance

Did the study show a meaningful human outcome?

A change in NAD+, PGC-1α, oxidative-stress markers, or gene expression can be useful without proving an improvement in strength, endurance, fatigue, recovery, cognition, metabolism, or quality of life.

05 · Exposure

Can the ingredient reach the tissues where it is expected to act?

Absorption and metabolism differ substantially. Chemical form, food, delivery system, gut metabolism, and rapid conversion into metabolites can all affect biological exposure.

06 · Tradeoffs

What are the safety, interaction, and cost considerations?

Useful comparison includes adverse events, study duration, medication interactions, relevant health conditions, and whether the monthly price reflects the labeled dose or the dose used in research.

Strong for a specific use

Replicated human evidence supports a defined outcome. That outcome may not represent broad mitochondrial improvement.

Moderate or context-specific

Human evidence exists, but the result depends on the population, formulation, dose, condition, or outcome measured.

Early or mixed

Human findings are promising, small, inconsistent, or limited to biomarkers and secondary outcomes.

Limited or primarily preclinical

Human mitochondrial evidence is sparse, indirect, exploratory, or based mainly on cell and animal research.

Ingredient	Main mitochondrial role	Human evidence	Main strength and limitation	Approx. 30-day cost
Mitochondrial signaling, biogenesis, and related polyphenol research
Mitozz Purified (−)-epicatechin, 98% purity	Mitochondrial signaling, biogenesis-related pathways, muscle biology, and emerging mitophagy and mitochondrial quality-control research.	Early human evidence Small pharmacokinetic and muscle-biopsy studies report changes in mitochondrial signaling and biogenesis-related markers. Mitophagy findings are currently supported by preclinical research.	Purified (−)-epicatechin has been studied directly in humans, with pharmacokinetic research confirming absorption and small muscle-biopsy studies reporting changes in mitochondrial structure, signaling, and biogenesis-related markers. Preclinical research also supports a potential role in mitophagy and mitochondrial quality control. The next step is larger controlled trials to establish how consistently these effects translate into measurable functional benefits. Also relevant to mitophagy and mitochondrial quality control.	$125
EGCG Epigallocatechin gallate	Polyphenol signaling, oxidative-stress pathways, and metabolic regulation.	Limited and mixed Human studies report selected physiological effects, but direct mitochondrial remodeling has not been established.	EGCG has a large mechanistic literature, but brewed tea and concentrated extracts are not equivalent. High-dose extracts can raise liver enzymes and have been linked to liver injury.	$4–$9
Resveratrol	Sirtuin, AMPK, vascular, and metabolic signaling.	Mixed human evidence Some studies report vascular or exercise-related effects, while several direct skeletal-muscle studies are null.	Resveratrol has an extensive research history, but results are inconsistent and the parent compound has low systemic exposure because it is rapidly metabolized.	$9–$35
Quercetina	Antioxidant signaling, exercise adaptation, and mitochondrial-dynamics pathways.	Emerging functional evidence A small trial reported greater strength gains with training, but direct mitochondrial evidence remains weak.	Recent functional findings are interesting, but aglycone, glycosides, phytosome products, and food forms have different exposure and should not be treated as interchangeable.	$9–$29
Apple procyanidins	Polyphenol oligomers associated with vascular and metabolic signaling.	Primarily indirect Some mixed-ingredient products report exercise effects, but isolated mitochondrial evidence is minimal.	Larger oligomers have low intact absorption and are transformed by gut metabolism. Products are often poorly standardized or contain multiple active ingredients.	$5–$17
Curcumina	Inflammatory, redox, recovery, and metabolic signaling.	Mixed indirect evidence Formulation-specific studies report selected recovery, vascular, or performance effects.	Native curcumin has very low exposure. Piperine, lipid, micellar, phytosome, and nanoparticle formulations are not interchangeable, and rare liver injury has been reported.	$9–$36
Dihydromyricetin DHM	Stress-response, antioxidant, liver, and metabolic signaling.	Early and primarily preclinical Human research focuses mainly on liver and metabolic markers, often in combination products.	DHM has an interesting proposed mechanism, but no isolated randomized trial has demonstrated a direct mitochondrial benefit. Human pharmacokinetic and long-term safety data are limited.	$25–$52
Genisteína	Isoflavone, metabolic, estrogen-receptor, and signaling pathways.	Context-specific and indirect Human trials support selected bone and menopausal outcomes, not broad mitochondrial improvement.	Genistein has relatively long human exposure data, but its mitochondrial positioning is supported mainly by preclinical research. Estrogenic and thyroid considerations apply.	$9–$74
PQQ Pyrroloquinoline quinone	Redox signaling and claims related to mitochondrial biogenesis.	Primarily exploratory Small human studies report selected biomarker or cognition signals.	A change in PGC-1α without improved performance or direct mitochondrial measurements does not establish the creation of new, functional mitochondria.	$8–$25
NAD+ precursors
NMN Nicotinamide mononucleotide	Precursor used to increase NAD-related metabolites.	Early and mixed NMN reliably raises blood NAD-related biomarkers, while functional outcomes are less consistent.	The biomarker effect is reproducible, but higher blood NAD-related metabolites have not been shown to consistently improve direct mitochondrial or functional outcomes.	$10–$65
NR Nicotinamide riboside	Precursor used to increase NAD-related metabolites.	Mixed human evidence NR changes circulating and muscle NAD-related metabolites, but direct muscle studies have largely been null.	NR has several direct skeletal-muscle studies, yet these studies generally found no improvement in mitochondrial respiration or bioenergetics.	$8–$74
Mitophagy and mitochondrial quality control Urolithin A has the most developed human clinical program in this category. Purified (−)-epicatechin also has emerging preclinical mitophagy evidence.
Urolitina A	Mitophagy and mitochondrial quality-control pathways.	Moderate human evidence Multiple trials report selected strength, endurance, recovery, or biomarker effects.	Urolithin A has one of the most developed human programs in this category. Several major trials also missed primary performance, ATP-related, or mitochondrial-respiration endpoints.	$39–$99
Electron transport, metabolic cofactors, and fatty-acid transport
CoQ10 Coenzyme Q10	Electron transport, membrane redox activity, and respiratory-chain function.	Moderate and context-specific Some clinical uses and mitochondrial measurements improve, while many direct muscle trials are null.	CoQ10 has a direct biochemical role and substantial clinical experience. Its essential role does not mean supplementation benefits every person, and formulation materially affects exposure.	$4–$45
Alpha-lipoic acid	Mitochondrial enzyme cofactor and redox support.	Moderate and context-specific Evidence is strongest for selected neuropathy and metabolic outcomes.	Alpha-lipoic acid has a defined biochemical role and substantial clinical experience, but most evidence concerns conditions other than direct mitochondrial performance.	$5–$34
L-carnitine / ALCAR	Mitochondrial fatty-acid transport and acetyl-group metabolism.	Moderate and context-specific Benefits are clearest in deficiency, selected mitochondrial disease, and specific clinical populations.	Carnitine has a direct mitochondrial role, but results in healthy adults are inconsistent when carnitine status is adequate. L-carnitine and ALCAR are not interchangeable.	$5–$35
Riboflavin Vitamin B2	FMN- and FAD-dependent mitochondrial enzyme support.	Strong in deficiency or responsive disease Riboflavin can produce substantial benefits in deficiency and defined riboflavin-responsive genetic disorders.	Riboflavin is an essential mitochondrial cofactor, but there is little evidence that high-dose supplementation broadly improves mitochondrial function in nutritionally replete adults.	$2–$16
Energy buffering, substrate support, and redox balance
Creatine	Phosphocreatine energy buffering and rapid ATP regeneration.	Strong for energy buffering Creatine has extensive replicated evidence for strength, power, training adaptation, and lean-mass outcomes.	Creatine has the largest functional evidence base in this comparison. Its proven mechanism is rapid cellular energy buffering, not mitochondrial biogenesis, mitophagy, or respiratory-chain remodeling.	$4–$15
D-ribose	Nucleotide substrate and claims related to ATP replenishment.	Limited human evidence Small studies report subgroup or recovery signals, while controlled performance findings are inconsistent.	D-ribose has a clear biochemical rationale, but no convincing evidence of improved mitochondrial function. Many labels provide less than the 10 to 15 grams used in several studies.	$9–$20 $18–$50 at research-range doses
Taurine	Mitochondrial translation, calcium handling, membrane stability, and osmotic regulation.	Mixed and context-specific Disease-specific and selected exercise studies report benefits, but broad anti-aging claims remain uncertain.	Taurine has plausible mitochondrial biology and direct disease-specific evidence. Recent human data do not support a universal age-related taurine-deficiency model.	$3–$10
GlyNAC Glycine plus N-acetylcysteine	Glutathione synthesis, redox balance, fuel oxidation, and cellular metabolic support.	Promising early evidence Small studies report improvements in glutathione, fuel oxidation, and selected functional measures.	The human findings are promising, but samples are small, research is concentrated in one group, and independent replication is lacking. Study doses are often much higher than commercial labels.	$30–$45 Research-matched cost uncertain

Mitochondrial biogenesis is the coordinated process through which cells expand and renew their mitochondrial network. It involves changes in nuclear and mitochondrial gene expression, protein synthesis, membrane formation, mitochondrial DNA, and integration into functioning organelles.

Researchers commonly measure upstream signals such as AMPK, SIRT1, PGC-1α, NRF1, or TFAM. These markers can indicate that a pathway has been activated, but they do not by themselves establish that new, fully functional mitochondria were produced.

The same caution applies to mitophagy. Changes in quality-control signaling may be biologically important, but direct evidence that damaged mitochondria were identified, removed, and replaced is more difficult to demonstrate in humans.

Purified (−)-epicatechin

A defined flavanol with human mitochondrial and muscle-biopsy research

Mitozz provides 100 mg per daily serving of purified 98% pure (−)-epicatechin. Its exact stereochemistry, purity, and dose are disclosed, allowing the product to be evaluated against research on the same defined compound rather than against cocoa, mixed extracts, or related oligomers.

Human pharmacokinetic studies show that (−)-epicatechin is absorbed and extensively metabolized after oral consumption. These studies establish human exposure to the compound and its metabolites rather than relying solely on cell or animal research.

Small human muscle-biopsy studies have reported changes in mitochondrial structure, mitochondrial signaling, and biogenesis-related markers following isolated (−)-epicatechin use. These findings place purified (−)-epicatechin among the relatively small group of polyphenol ingredients studied directly in human muscle tissue.

Preclinical research also supports a potential role in mitophagy and mitochondrial quality control. This suggests that the compound may influence not only pathways involved in building mitochondrial capacity, but also processes involved in identifying and recycling damaged or unneeded mitochondria.

The mitophagy evidence has not yet been established in humans, and larger controlled trials are needed to determine how consistently the observed biological changes translate into measurable strength, endurance, recovery, or other functional outcomes.

Human exposure Direct pharmacokinetic evidence
Oral absorption and extensive metabolism have been measured in humans.
Biogenesis Early human tissue evidence
Small muscle-biopsy studies report mitochondrial and biogenesis-related changes.
Mitofagia Emerging preclinical evidence
Effects on mitochondrial quality-control pathways have not yet been demonstrated in humans.
Formulation Exact identity and dose disclosed
Purified (−)-epicatechin is not equivalent to cocoa, mixed flavanol products, (+)-epicatechin, or procyanidin oligomers.

Related ingredients

Other ingredients marketed around signaling or biogenesis

These ingredients have plausible biological mechanisms, but the directness and consistency of their human mitochondrial evidence vary. Extracts, purified compounds, food sources, and enhanced-delivery formulations should not be treated as interchangeable.

Limited and mixed

EGCG

EGCG influences redox, metabolic, and stress-response pathways and has a large mechanistic literature. Human studies report selected physiological effects, but direct mitochondrial remodeling has not been established. Brewed tea and concentrated extracts are not equivalent, and high-dose extracts can raise liver enzymes or cause liver injury.

Mixed human evidence

Resveratrol

Resveratrol is associated with SIRT1, AMPK, and metabolic signaling. Some controlled studies report vascular or exercise-related effects, while several direct muscle studies are null. The parent compound has low systemic exposure because it is rapidly metabolized, making formulation and dose important.

Emerging functional evidence

Quercetina

Quercetin has been studied in relation to exercise adaptation, oxidative-stress pathways, and mitochondrial dynamics. A small controlled trial reported greater strength gains during training, but replicated direct evidence for improved mitochondrial respiration or content is lacking.

Primarily indirect

Apple procyanidins

Mixed grape-and-apple products have reported selected exercise or vascular effects, but isolated human mitochondrial research is minimal. Larger procyanidin oligomers have low intact absorption and are extensively transformed through digestion and gut metabolism.

Mixed indirect evidence

Curcumina

Curcumin affects inflammatory, redox, and metabolic pathways. Formulation-specific studies report selected recovery, vascular, or performance effects, but direct mitochondrial outcomes remain sparse. Native curcumin has low exposure, and piperine, lipid, micellar, and nanoparticle products are not interchangeable.

Early and preclinical

Dihidromiricetina

Dihydromyricetin has proposed effects on liver, antioxidant, and metabolic signaling. Human studies are limited and frequently use combination products. There is currently no isolated randomized trial demonstrating a direct mitochondrial benefit.

Context-specific

Genisteína

Genistein has substantial human research for bone, menopausal, and estrogen-related outcomes. Its mitochondrial positioning is based primarily on preclinical signaling research. Purified genistein and mixed soy isoflavones differ, and thyroid and hormone-sensitive considerations may be relevant.

Primarily exploratory

PQQ

PQQ is frequently marketed as a mitochondrial-biogenesis ingredient, but human research remains small and exploratory. A change in PGC-1α or another upstream marker does not establish that new, functional mitochondria were produced, particularly when direct function or performance did not improve.

Section summary

Key points

Polyphenol ingredients differ in chemical form, metabolism, dose, and tissue exposure.
An upstream marker such as PGC-1α does not by itself prove the creation of new, functional mitochondria.
Research on cocoa or mixed extracts should not automatically be attributed to purified (−)-epicatechin.

Purified (−)-epicatechin has direct human pharmacokinetic data and early human muscle-biopsy evidence related to mitochondrial structure and biogenesis.
Its mitophagy evidence is promising but currently preclinical.
For most other ingredients in this group, direct human mitochondrial outcomes remain limited, mixed, or highly formulation-dependent.

Nicotinamide adenine dinucleotide, or NAD+, is involved in energy metabolism, redox reactions, DNA repair, and cellular signaling. Its biological importance makes NAD+ an attractive target for supplementation.

NMN and NR are both precursors used by the body to produce NAD-related metabolites. Human studies consistently show that these compounds can alter NAD-related measurements in blood, and in some cases in muscle or other tissues.

The unresolved question is what those changes mean. A higher concentration of an NAD-related biomarker does not automatically demonstrate improved mitochondrial respiration, greater ATP production, better physical function, or slower biological aging.

What the research establishes

Three findings should be kept separate

NAD+ precursor research is easiest to interpret when biomarker response, tissue response, and functional response are evaluated as different questions.

Established

NAD-related biomarkers can increase

Both NMN and NR can raise selected NAD-related metabolites in humans. This is the most consistent finding in the clinical literature and supports their classification as NAD+ precursors.

Variable

Tissue response is not uniform

Changes measured in blood do not necessarily reflect changes in skeletal muscle, brain, liver, or other tissues. Dose, duration, age, health status, chemical form, and baseline NAD metabolism may all affect the response.

Unresolved

Functional benefit is inconsistent

Selected studies report improvements in secondary or exploratory outcomes, but controlled trials have not consistently shown better mitochondrial respiration, exercise performance, strength, insulin sensitivity, fatigue, or other functional outcomes.

Side-by-side comparison

NMN and NR produce similar marketing claims, but their research programs differ

Neither ingredient should be judged solely by whether it raises an NAD-related biomarker. The more important question is whether the increase produces a reproducible mitochondrial or functional benefit.

Early and mixed human evidence

NMN

Nicotinamide mononucleotide

NMN reliably changes blood NAD-related biomarkers. Some small studies report improvements in selected metabolic, sleep, exercise, or physical-function measurements, but the overall functional evidence remains inconsistent.

Main strength: consistent evidence that oral NMN can alter NAD-related biomarkers.
Main limitation: biomarker changes have not been shown to consistently improve direct mitochondrial measurements or primary functional outcomes.
Purity, stability, dose, storage, tissue distribution, and product quality may affect interpretation.
Short-term studies generally report acceptable tolerance, but long-term safety and clinical-outcome data remain limited.

Approximate 30-day retail cost $10–$65

Mixed human evidence

NR

Nicotinamide riboside

NR has well-described human pharmacokinetic research and reliably changes circulating and muscle NAD-related metabolites. Several direct skeletal-muscle studies, however, found no improvement in mitochondrial respiration or bioenergetics.

Main strength: a developed human research program that includes direct skeletal-muscle measurements.
Main limitation: the direct muscle studies have largely not shown improved mitochondrial respiration or energy metabolism.
Salts, formulations, doses, and tissue responses may differ between products and studies.
Short-term tolerance is generally acceptable, but long-term outcome evidence remains uncertain.

Approximate 30-day retail cost $8–$74

Interpreting the evidence

Biomarker response and mitochondrial response are not the same result

NMN and NR can both be described accurately as NAD+ precursors. More specific claims require evidence that the metabolic change produced a direct mitochondrial or meaningful functional effect.

NAD-related biomarkers

NMN Blood NAD-related biomarkers generally increase. Tissue-specific effects are less consistently characterized.

NR Circulating and muscle NAD-related metabolites reliably change in several controlled studies.

Direct mitochondrial measurements

NMN Direct evidence for improved human mitochondrial respiration, ATP production, or mitochondrial content remains limited.

NR Several skeletal-muscle studies directly measured mitochondrial outcomes and generally found no meaningful improvement.

Functional outcomes

NMN Selected secondary outcomes have improved in small studies, but primary performance and metabolic findings are inconsistent.

NR Changes in strength, endurance, metabolism, or physical function have generally been small, absent, or dependent on the population studied.

Practical considerations

NMN Product purity, stability, storage, dose, and regulatory status can vary across markets.

NR Chemical salt, formulation, dose, treatment duration, and baseline health may affect exposure and response.

Section summary

Key points

NMN and NR reliably alter selected NAD-related biomarkers in humans.
A change measured in blood does not necessarily demonstrate a comparable change in muscle, brain, liver, or another target tissue.
NMN has promising small-study findings, but direct mitochondrial and functional results remain early and mixed.

NR has several direct skeletal-muscle studies, but these studies largely found no improvement in mitochondrial respiration or bioenergetics.
Short-term tolerance appears generally acceptable for both ingredients, while long-term outcome and safety evidence remain limited.
NAD+ biomarker elevation should not be presented as proof of improved mitochondrial function or slower aging.

Mitophagy is the selective removal of mitochondria through the cell’s autophagy and lysosomal systems. It is one part of a broader quality-control network that also includes mitochondrial fusion, fission, protein repair, antioxidant defenses, and biogenesis.

The objective is not to eliminate every older mitochondrion. Healthy cells continually evaluate mitochondrial performance and adjust the network according to energy demand, damage, nutrient availability, stress, and tissue function.

Directly demonstrating mitophagy in living humans is difficult. Researchers often rely on pathway markers, gene expression, mitochondrial proteins, tissue biopsies, imaging, or downstream changes in muscle function and metabolism.

Quality-control framework

Mitochondrial renewal requires both removal and replacement

Mitophagy is often described as a single event, but effective mitochondrial quality control requires several coordinated steps.

Damage recognition

Cells detect changes in membrane potential, protein integrity, oxidative stress, calcium handling, respiration, or other signs that a mitochondrion is no longer functioning normally.

Isolation from the network

Mitochondrial fission can separate a damaged region from the larger network, allowing the cell to preserve functioning components while targeting the impaired portion for further evaluation.

Removal and recycling

Selected mitochondria are enclosed within autophagic structures and delivered to lysosomes, where their components can be broken down and recycled.

Rebuilding capacity

Biogenesis, protein synthesis, membrane formation, and mitochondrial network remodeling help replace what was removed and maintain sufficient mitochondrial capacity for the cell.

Ingredient comparison

Urolithin A and purified (−)-epicatechin have different evidence profiles

Urolithin A has the most developed human clinical program focused specifically on mitophagy and mitochondrial quality control. Purified (−)-epicatechin has human evidence related to mitochondrial structure and biogenesis, together with emerging cellular evidence related to mitophagy. In a laboratory study, isolated (−)-epicatechin induced mitophagy in normal human fibroblast cells.

Moderate human evidence

Urolitina A

Purified postbiotic metabolite

Urolithin A has been evaluated in multiple controlled human trials measuring mitochondrial biomarkers, muscle endurance, strength, recovery, and physical function.

Main strength: one of the most developed human research programs for an ingredient positioned specifically around mitophagy.
Several trials report changes in selected mitochondrial, inflammatory, endurance, strength, or recovery measurements.
Purified urolithin A should not be treated as equivalent to eating pomegranate because individual gut conversion varies substantially.
Main limitation: several major trials did not improve primary performance, ATP-related, or mitochondrial respiration outcomes.
Much of the clinical program is connected to a limited number of sponsors and research networks.

Approximate 30-day retail cost $39–$99

Early human evidence with cellular mitophagy findings

Purified (−)-epicatechin

Mitozz provides 100 mg per daily serving

Purified (−)-epicatechin has been studied directly in humans, with pharmacokinetic data confirming exposure and small muscle-biopsy studies reporting mitochondrial structural and biogenesis-related changes.

Main strength: human evidence extends beyond a general antioxidant claim to mitochondrial structure, signaling, muscle biology, and biogenesis-related markers.
A laboratory study found that isolated (−)-epicatechin induced mitophagy in normal human fibroblast cells.
This provides a biologically relevant connection between mitochondrial replacement and mitochondrial cleanup, but the finding comes from a cell model rather than a supplementation trial.
The exact compound, stereochemistry, purity, and daily dose are disclosed.
Main limitation: this mitophagy effect has not yet been demonstrated in a human supplementation trial.

Approximate 30-day retail cost $125

Interpreting the evidence

A mitophagy claim can be supported at several different levels

The evidence becomes stronger as research moves from pathway plausibility to direct human tissue measurements and meaningful functional outcomes.

Biological mechanism

Urolithin A Preclinical and translational research supports effects on mitophagy-related pathways and mitochondrial quality-control signaling.

Purified (−)-epicatechin A laboratory study found that isolated (−)-epicatechin induced mitophagy in normal human fibroblast cells, supporting a potential influence on mitochondrial turnover and related quality-control pathways.

Human tissue evidence

Urolithin A Human trials include mitochondrial biomarkers and muscle-related measurements, although direct confirmation of the complete mitophagy process remains difficult.

Purified (−)-epicatechin Small human muscle-biopsy studies report mitochondrial structural and biogenesis-related changes. The direct mitophagy finding comes from normal human fibroblast cells and has not yet been demonstrated in a human supplementation trial.

Direct mitochondrial function

Urolithin A Some mitochondrial and endurance-related measurements improve, but major trials have also reported null respiration, ATP, and primary performance outcomes.

Purified (−)-epicatechin Human findings support mitochondrial pathway and structural effects, while larger controlled studies of respiration, ATP production, and functional outcomes remain needed.

Functional outcomes

Urolithin A Selected studies report improvements in endurance, strength, recovery, or physical function, but effects are not consistent across all primary outcomes.

Purified (−)-epicatechin Small human studies provide early functional and muscle-related signals, but a replicated functional benefit has not yet been established in a large placebo-controlled trial.

Section summary

Key points

Mitophagy is one part of a broader mitochondrial quality-control system.
Effective renewal requires coordinated damage recognition, removal, recycling, and replacement.
Changes in mitophagy-related markers do not automatically prove that damaged mitochondria were removed or that tissue function improved.

Urolithin A has the most developed human clinical program focused specifically on mitophagy.
Purified (−)-epicatechin combines early human mitochondrial and biogenesis-related evidence with emerging cellular mitophagy research.
More mitochondrial removal is not necessarily beneficial unless replacement and functional capacity are also maintained.

Mitochondria require a continuous supply of vitamins, cofactors, electron carriers, substrates, and transport molecules. Without them, the reactions involved in fuel oxidation and ATP production cannot proceed normally.

This does not mean that taking more of every required molecule will increase mitochondrial output. In many cases, supplementation produces the clearest benefit when there is a deficiency, impaired synthesis, increased demand, medication effect, genetic disorder, or defined clinical condition.

The central distinction is between proving that a molecule is necessary for mitochondrial metabolism and proving that additional intake improves mitochondrial function in a person who already has adequate status.

Functional framework

These ingredients support different parts of mitochondrial metabolism

CoQ10, alpha-lipoic acid, carnitine, and riboflavin all have direct biochemical relationships with mitochondrial function, but they are not interchangeable.

Electron carrier

CoQ10

CoQ10 transfers electrons within the inner mitochondrial membrane and also participates in membrane redox balance. Its role in the respiratory chain is direct and essential.

Enzyme cofactor

Alpha-lipoic acid

Lipoic acid is required by mitochondrial enzyme complexes involved in oxidative metabolism. Supplemental alpha-lipoic acid is also used for its redox and metabolic effects.

Fuel transport

L-carnitine and ALCAR

Carnitine supports the movement of long-chain fatty acids into mitochondria for oxidation. Acetyl-L-carnitine also carries an acetyl group and is studied in neurological and metabolic contexts.

Flavin precursor

Riboflavin

Riboflavin is used to produce FMN and FAD, cofactors required by numerous mitochondrial enzymes, including components of electron transport and fatty-acid oxidation.

Ingredient comparison

Direct biochemical roles, different clinical evidence

The strength of evidence depends on the outcome being claimed. Each ingredient has a legitimate mitochondrial role, but broad claims of greater energy or universally improved mitochondrial function are not equally supported.

Moderate and context-specific

CoQ10

Coenzyme Q10

CoQ10 is a direct component of electron transport and has one of the longest clinical histories among mitochondrial supplements.

Main strength: a clearly defined role in the respiratory chain and substantial human clinical experience.
Evidence is most compelling in selected deficiency states, mitochondrial disorders, medication-associated depletion, and certain clinical populations.
Ubiquinone and ubiquinol formulations can differ in absorption, dose, and cost.
Main limitation: many trials in generally healthy or nondeficient adults do not show improved muscle mitochondrial function or physical performance.
CoQ10 can interact with warfarin and should be considered in the context of anticoagulant management.

Approximate 30-day retail cost $4–$45

Moderate and context-specific

Alpha-lipoic acid

ALA

Alpha-lipoic acid is related to mitochondrial enzyme function and has also been studied for metabolic, redox, and neuropathy-related effects.

Main strength: a defined biochemical relationship with mitochondrial oxidative metabolism and substantial human research.
Clinical evidence is strongest for selected neuropathy and metabolic outcomes rather than broad mitochondrial enhancement.
R-lipoic acid, racemic alpha-lipoic acid, sustained-release products, and different doses may produce different exposure.
Main limitation: improvement in a neuropathy or glucose-related outcome does not prove improved mitochondrial respiration in healthy adults.
Alpha-lipoic acid can lower blood glucose and has been associated with rare insulin autoimmune syndrome in susceptible individuals.

Approximate 30-day retail cost $5–$34

Moderate and context-specific

L-carnitine and ALCAR

L-carnitine and acetyl-L-carnitine

Carnitine has a direct role in fatty-acid transport, while ALCAR has additional acetyl-group and neurological positioning.

Main strength: direct mitochondrial relevance and clear benefit in carnitine deficiency and selected metabolic or mitochondrial disorders.
Evidence also exists in specific neurological, cardiovascular, exercise-recovery, and fertility contexts.
L-carnitine and ALCAR should not be treated as identical products because their distribution and research applications differ.
Main limitation: oral supplementation does not consistently increase muscle carnitine or improve performance in healthy adults with adequate status.
Gastrointestinal effects, fish-like odor, medication considerations, and individual metabolism may affect use.

Approximate 30-day retail cost $5–$35

Strong for deficiency or responsive disease

Riboflavin

Vitamin B2

Riboflavin is an essential precursor for FMN and FAD and is indispensable for numerous mitochondrial enzyme reactions.

Main strength: strong evidence for correcting deficiency and for defined riboflavin-responsive genetic or metabolic disorders.
Riboflavin can produce substantial clinical effects when impaired flavin metabolism is a true bottleneck.
It is inexpensive, widely available, and generally well tolerated.
Main limitation: there is little evidence that high-dose riboflavin broadly improves mitochondrial function in nutritionally replete adults.
Bright yellow urine is an expected effect of excess riboflavin excretion and does not indicate greater mitochondrial uptake.

Approximate 30-day retail cost $2–$16

Interpreting the evidence

Four questions clarify when a mitochondrial cofactor is likely to help

The practical value of these ingredients depends on whether the relevant pathway is limited, whether the supplement reaches the target tissue, and whether the study outcome matches the claim.

Is there a deficiency?

Higher likelihood of benefit Documented nutritional deficiency, impaired synthesis, genetic disease, medication-associated depletion, malabsorption, or a clinically defined insufficiency.

Lower certainty Adequate status in a generally healthy adult with no evidence that the nutrient or cofactor is limiting metabolism.

Does it reach the tissue?

Important variables Chemical form, dose, absorption, transport, tissue uptake, treatment duration, baseline status, and interactions with food or medication.

Common error Assuming that increased blood concentration proves increased mitochondrial availability in muscle, brain, heart, or another target tissue.

What was measured?

Stronger evidence Direct mitochondrial respiration, enzyme activity, tissue concentration, ATP-related measurements, physical function, or a defined clinical outcome.

Weaker inference A biochemical rationale, blood biomarker, antioxidant measurement, or symptom change without a direct connection to mitochondrial function.

Is the form comparable?

Examples Ubiquinone versus ubiquinol, L-carnitine versus ALCAR, R-lipoic acid versus racemic ALA, and food-level riboflavin versus pharmacological dosing.

Why it matters Evidence from one chemical form, formulation, dose, or clinical population should not automatically be transferred to another.

Section summary

Key points

CoQ10, alpha-lipoic acid, carnitine, and riboflavin have direct biochemical relationships with mitochondrial metabolism.
Their most convincing benefits usually occur in deficiency, impaired metabolism, medication effects, genetic disease, or defined clinical populations.
The essential role of a molecule does not prove that additional intake improves mitochondrial function in a replete person.

CoQ10 evidence depends strongly on population, formulation, dose, and the outcome measured.
L-carnitine and ALCAR are related but should not be treated as interchangeable.
Riboflavin has strong evidence in deficiency and responsive disease, but not as a universal mitochondrial enhancer in adequately nourished adults.

Cellular energy depends on more than the production of ATP inside mitochondria. Cells also require systems that buffer ATP demand, provide metabolic substrates, maintain redox balance, stabilize membranes, and coordinate fuel use .

A supplement can improve strength, recovery, exercise capacity, redox balance, or a metabolic marker without directly increasing the number of mitochondria or improving the respiratory chain.

Purified (−)-epicatechin is relevant to this section because its mitochondrial profile includes redox regulation in addition to signaling, biogenesis-related pathways, muscle biology, and emerging cellular evidence related to mitophagy.

Functional framework

Different ingredients support different parts of cellular energy and redox control

These supplements should be compared according to the process they influence rather than grouped under a single general claim of increasing energy or acting as antioxidants.

Energy buffering

Creatine

Creatine increases the availability of phosphocreatine, which helps cells regenerate ATP rapidly during short periods of high energy demand. This supports power and repeated muscular effort without requiring a claim of mitochondrial remodeling.

Nucleotide substrate

D-ribose

D-ribose is a sugar used in nucleotide synthesis and is marketed as a substrate for replenishing depleted adenine nucleotides. A valid biochemical role does not establish that supplementation increases mitochondrial ATP production in healthy adults.

Cellular regulation

Taurine

Taurine participates in calcium handling, osmotic balance, membrane stability, mitochondrial translation, and other cellular processes. Its effects depend on the tissue, population, dose, and outcome studied.

Glutathione support

GlyNAC

GlyNAC combines glycine and N-acetylcysteine, two substrates used in glutathione synthesis. Research examines whether improving glutathione availability also affects fuel oxidation, oxidative stress, and physical function.

Redox regulation

Purified (−)-epicatechin

Research on purified (−)-epicatechin extends beyond direct radical scavenging. Preclinical studies report effects on mitochondrial superoxide, glutathione redox balance, endogenous antioxidant enzymes, mitochondrial signaling, and cellular responses to oxidative stress.

Ingredient comparison

Functional evidence ranges from highly established to promising but early

Creatine has extensive replicated human evidence for a defined energy-buffering function. Evidence for D-ribose, taurine, GlyNAC, and purified (−)-epicatechin depends more heavily on the population, dose, outcome, and biological process being evaluated.

Strong for energy buffering

Creatine

Commonly studied as creatine monohydrate

Creatine has extensive replicated evidence for increasing phosphocreatine availability and supporting strength, power, repeated high-intensity effort, and training adaptation.

Main strength: the largest and most consistent functional evidence base among the ingredients in this section.
Creatine monohydrate is the most established form and is typically less expensive than newer branded forms.
Its benefit is based primarily on cellular-energy buffering and rapid ATP regeneration during high demand.
Main limitation: its established effects should not be described as proof of mitochondrial biogenesis, mitophagy, or respiratory-chain remodeling.
Increased intracellular water and modest weight gain can occur and may reflect greater muscle creatine storage.

Approximate 30-day retail cost $4–$15

Limited human evidence

D-ribose

Pentose sugar used in nucleotide synthesis

D-ribose has a clear biochemical relationship with nucleotide synthesis and ATP-pool restoration, but controlled evidence for improved mitochondrial function or general physical performance is limited.

Main strength: a plausible substrate-based mechanism studied in selected cardiac, fatigue, and exercise-recovery settings.
Small studies report selected symptom, recovery, or subgroup findings.
Controlled performance findings are inconsistent and do not demonstrate broad mitochondrial improvement.
Main limitation: many commercial labels provide less than the 10 to 15 grams per day used in several research protocols.
D-ribose can lower blood glucose and may cause gastrointestinal discomfort in some users.

Approximate 30-day retail cost $9–$20 Approximately $18–$50 at research-range daily doses

Mixed and context-specific

Taurine

Sulfur-containing amino acid derivative

Taurine has biologically relevant roles in mitochondrial translation, calcium handling, membrane stability, osmotic balance, and cellular stress responses.

Main strength: broad biological relevance and human research across cardiovascular, metabolic, exercise, and disease-specific settings.
Selected studies report improvements in exercise, metabolic, or clinical outcomes.
The evidence varies substantially by population and should not be generalized across all adults.
Main limitation: recent human evidence does not support circulating taurine as a universal marker of aging. In a 2025 study of 137 men aged 20 to 93, serum taurine was not associated with age, muscle mass, strength, physical performance, or skeletal-muscle mitochondrial function.
These findings do not rule out potential benefits of taurine supplementation in people with low taurine status or specific clinical conditions.

Approximate 30-day retail cost $3–$10

Promising early human evidence

GlyNAC

Glycine plus N-acetylcysteine

Small human studies report improvements in glutathione status, fuel oxidation, oxidative-stress measurements, and selected physical or metabolic outcomes.

Main strength: research evaluates multiple connected outcomes rather than relying only on a general antioxidant claim.
The combination supplies two substrates used in glutathione synthesis.
Early findings include changes in redox balance, fuel oxidation, insulin-related measures, and selected functional outcomes.
Main limitation: studies are small, much of the research comes from one investigative group, and independent replication is limited.
Research protocols often use gram-level doses substantially higher than the amounts provided by many commercial products.

Approximate 30-day retail cost $30–$45 Research-matched dosing may cost more

Early human and emerging cellular evidence

Purified (−)-epicatechin

Defined flavanol stereoisomer

Purified (−)-epicatechin has been studied across mitochondrial signaling, structure, biogenesis-related pathways, muscle biology, and redox regulation. A laboratory study also found that isolated (−)-epicatechin induced mitophagy in normal human fibroblast cells.

Mitozz 30-day retail cost $125 100 mg daily serving of (−)-epicatechin made with 98% pure raw material

Main strength: exact compound identity, stereochemistry, purity, dose, human pharmacokinetic research, and direct human muscle-biopsy evidence.
Human studies have reported mitochondrial structural and signaling changes together with muscle-growth signaling, handgrip strength, appendicular muscle mass index, and functional mobility findings.
Cellular and preclinical studies report effects on mitochondrial superoxide, glutathione balance, endogenous antioxidant enzymes, and responses to oxidative stress.
Its redox profile is part of a broader mitochondrial mechanism rather than a simple claim that the compound directly neutralizes all reactive oxygen species.
Main limitation: human studies focusing specifically on direct redox outcomes remain limited. Larger independent trials are also needed to confirm how consistently the broader mitochondrial and muscle-related findings occur.

Interpreting the evidence

Match the claim to the biological system that changed

These ingredients illustrate why cellular-energy and antioxidant claims require precise language. A positive study can be meaningful without proving that mitochondrial number, respiration, or quality control improved.

What is supported?

More direct findings Increased muscle creatine, greater phosphocreatine availability, improved strength or power, altered glutathione status, changes in redox signaling, human muscle-biopsy findings, or a defined metabolic or functional outcome.

What should not be assumed That every improvement in energy, fatigue, strength, muscle mass, or redox balance reflects increased mitochondrial content or improved respiratory-chain function.

Antioxidant or redox effect?

Antioxidant substrate GlyNAC supplies precursors used to produce glutathione, increasing the availability of molecules involved in cellular redox defense.

Redox regulation Purified (−)-epicatechin is studied for effects on mitochondrial signaling, endogenous antioxidant enzymes, glutathione balance, mitochondrial superoxide, and cellular responses to oxidative stress.

Does the dose match?

Commercial serving The quantity shown on a supplement label may be selected for convenience, cost, capsule size, or marketing rather than to match a research protocol.

Research serving D-ribose and GlyNAC studies frequently use gram-level daily doses. Purified-compound epicatechin studies commonly use much smaller milligram doses, making exact identity and purity especially important.

Who was studied?

Higher relevance Results are most applicable when the product form, dose, population, baseline status, and outcome resemble the intended user and claim.

Lower certainty Findings from deficiency, chronic disease, older adults, sarcopenia, or metabolically impaired participants may not apply equally to healthy younger adults.

Was it replicated?

Established evidence Multiple independent controlled studies produce similar findings across relevant populations and outcomes.

Early evidence Small human trials, tissue-level findings, or preclinical redox studies can support a promising conclusion while still requiring larger independent confirmation.

Section summary

Key points

Creatine has strong replicated evidence for energy buffering, strength, power, and training adaptation.
Creatine’s functional evidence does not establish mitochondrial biogenesis, mitophagy, or respiratory-chain remodeling.
D-ribose has a plausible substrate-based mechanism, but direct evidence for improved mitochondrial function remains limited.
Taurine has important mitochondrial and cellular roles, but a 2025 human study found no association between circulating taurine and age, muscle mass, strength, physical performance, or skeletal-muscle mitochondrial function.

GlyNAC has promising early human findings related to glutathione, fuel oxidation, and physical function, but broader independent replication is still needed.
Purified (−)-epicatechin has human evidence related to exposure, mitochondrial structure, signaling, muscle-growth signaling, strength, appendicular muscle mass index, and functional mobility.
A laboratory study found that isolated (−)-epicatechin induced mitophagy in normal human fibroblast cells, but this effect has not yet been demonstrated in a human supplementation trial.
Its redox evidence includes mitochondrial superoxide, glutathione balance, endogenous antioxidant enzymes, and cellular responses to oxidative stress, with the most direct redox evidence currently coming from cellular and preclinical research.
Research-range doses can differ substantially from commercial label servings and may change the true monthly cost.

Mitozz does not belong exclusively to a single category in this comparison. Purified (−)-epicatechin has been studied across several connected parts of mitochondrial biology rather than as a nutrient that replaces one missing cofactor or as a substrate that produces an immediate increase in ATP.

Its strongest current distinction is the combination of exact compound identity, human pharmacokinetic research, direct human muscle-biopsy findings, and reported human muscle and functional outcomes within a broader profile that includes mitochondrial signaling, biogenesis-related markers, redox balance, and emerging cellular evidence related to mitophagy.

Human studies have reported changes in mitochondrial structure and signaling as well as improvements in handgrip strength, appendicular muscle mass index, functional mobility, and muscle-growth signaling. Larger independent trials are still needed to establish how consistently these findings occur across different populations.

Product and compound profile

A defined dose of a defined stereoisomer

Purified (−)-epicatechin should not be treated as interchangeable with cocoa, chocolate, mixed flavanol extracts, apple procyanidins, (+)-epicatechin, or other structurally related compounds.

Active compound (−)-epicatequina

The naturally occurring stereoisomer used in the relevant purified-compound research.

Raw-material purity 98% pure

Purity and compound identity are specified rather than described only as a general botanical extract.

Daily serving 100 mg

Two 50 mg capsules per daily serving.

Supply and price 30 days · $125

Sixty capsules per bottle at the standard daily serving.

Stereochemistry matters because molecules with the same molecular formula can interact differently with enzymes, receptors, transport systems, and cellular pathways. Evidence from another stereoisomer should not automatically be attributed to purified (−)-epicatechin.

Purity also matters. Research on a defined isolated compound allows an observed effect to be linked more directly to that compound than research on cocoa, tea, fruit extracts, or multi-ingredient formulas.

Mitozz uses a daily serving that falls within the range used in purified-compound human research. This does not guarantee the same outcome in every population, but it makes the product more directly comparable with the relevant evidence.

Not equivalent to Cocoa or chocolate
Foods contain multiple flavanols, procyanidins, nutrients, and other compounds.
Not equivalent to Mixed botanical extracts
Extract composition, standardization, absorption, and effective dose can vary substantially.
Not equivalent to Procyanidin oligomers
Larger flavanol oligomers have different absorption and metabolic characteristics.
Research advantage Exact-compound comparison
Identity, stereochemistry, purity, and dose can be matched more directly to purified-compound studies.

Evidence profile

The evidence extends across several levels of mitochondrial and muscle biology

Not every finding has the same level of support. Human exposure, tissue-level findings, strength, muscle-mass, and mobility outcomes have been reported. The direct mitophagy finding comes from a laboratory study using normal human fibroblast cells, while the redox evidence remains primarily cellular and preclinical.

Human evidence

Absorption and metabolism

Human pharmacokinetic studies show that orally consumed (−)-epicatechin is absorbed and extensively converted into sulfate, glucuronide, and methylated metabolites.

Human tissue evidence

Mitochondrial structure and signaling

Small human muscle-biopsy studies report changes in mitochondrial structure, mitochondrial enzyme activity, signaling pathways, and biogenesis-related markers.

Human evidence

Muscle-growth signaling

Human research has reported changes in the balance between follistatin and myostatin, two signaling systems associated with muscle growth and muscle-loss regulation.

Human functional evidence

Strength, muscle mass, and mobility

Human studies have reported improvements in handgrip strength, appendicular muscle mass index, functional mobility, and selected resistance-training outcomes. Larger independent trials are needed to establish how consistently these effects occur.

Cellular evidence

Mitophagy and quality control

A laboratory study found that isolated (−)-epicatechin induced mitophagy in normal human fibroblast cells. This provides early cellular evidence related to mitochondrial quality control, but the effect has not yet been demonstrated in a human supplementation trial.

Emerging evidence

Mitochondrial redox regulation

Cellular and preclinical studies report effects on mitochondrial superoxide, glutathione balance, endogenous antioxidant systems, and responses to oxidative stress.

Position within the comparison

How Mitozz differs from the other major supplement categories

Mitozz is not intended to duplicate every other mitochondrial supplement. It occupies a different position within the wider mitochondrial support landscape.

Versus NAD+ precursors

More than a blood biomarker

NMN and NR reliably change NAD-related metabolites. Purified (−)-epicatechin has direct human muscle-biopsy evidence and reported human muscle and functional outcomes rather than relying only on a circulating biomarker.

Versus cofactors

Signaling rather than replacement

CoQ10, riboflavin, carnitine, and alpha-lipoic acid have direct biochemical roles and can be highly relevant when a pathway is deficient or impaired. Mitozz is positioned around mitochondrial adaptation and signaling, not the correction of a known nutrient deficiency.

Versus creatine

Broader muscle and mitochondrial signaling

Creatine has strong evidence for phosphocreatine-based energy buffering and performance. Purified (−)-epicatechin is studied in relation to mitochondrial structure, biogenesis-related pathways, muscle-growth signaling, strength, muscle mass, redox signaling, and quality control .

Versus Urolithin A

Broader profile, cellular mitophagy evidence

Urolithin A has the more developed human clinical program centered specifically on mitophagy. Purified (−)-epicatechin has a broader emerging profile across human muscle biology, strength, muscle mass, mitochondrial structure, biogenesis-related signaling, and redox regulation, together with cellular evidence that isolated (−)-epicatechin induced mitophagy in normal human fibroblast cells in a laboratory study.

Versus botanical extracts

Exact identity and dose

Cocoa, tea, apple, grape, turmeric, and other extracts contain mixtures of compounds. Mitozz provides a defined stereoisomer at a disclosed purity and dose , allowing a closer match to exact-compound research.

Practical interpretation

The clearest strengths and current research opportunities

A balanced assessment should recognize the human muscle and functional findings that already exist while remaining clear about the need for broader independent confirmation.

Main strengths

Defined compound with direct human research

Mitozz discloses the stereoisomer, purity, dose, and serving. Human research includes pharmacokinetic studies, direct muscle-biopsy measurements, muscle-growth signaling, strength, muscle-mass, and functional-mobility outcomes.

Breadth of mechanism

Multiple connected mitochondrial and muscle pathways

Purified (−)-epicatechin is associated with mitochondrial signaling, structure, biogenesis-related pathways, muscle-growth regulation, redox regulation, and vascular signaling, together with emerging cellular evidence related to mitophagy.

Human findings

Strength, muscle mass, and mobility have been studied

Human studies have reported improvements in handgrip strength, appendicular muscle mass index, functional mobility, and selected resistance-training outcomes, along with changes in muscle-growth signaling.

Current research opportunity

Confirming promising muscle and functional findings

The next research step is to confirm the existing strength, muscle-mass, mobility, signaling, and mitochondrial findings in larger, independently replicated, placebo-controlled trials across different populations.

View Mitozz product details

Section summary

Key points

Mitozz provides 100 mg per daily serving of purified (−)-epicatechin made with 98% pure raw material.
Its exact stereochemistry, purity, dose, and serving are disclosed.
Human research includes pharmacokinetic studies and direct muscle-biopsy findings related to mitochondrial structure, signaling, enzymes, and biogenesis-associated markers.
Human studies have also reported improvements in handgrip strength, appendicular muscle mass index, functional mobility, and muscle-growth signaling.

Purified (−)-epicatechin should not be treated as equivalent to cocoa, mixed flavanol extracts, or procyanidin oligomers.
Its broader profile includes muscle biology, redox regulation, vascular signaling, and emerging cellular evidence related to mitophagy.
The direct mitophagy evidence comes from laboratory cell research, while the redox evidence is currently strongest in cellular and preclinical research.
The principal research opportunity is broader independent confirmation of the promising mitochondrial, muscle, strength, and functional findings already reported.

The purpose of the review is not to identify one universal mitochondrial supplement. It is to determine what each ingredient has actually been shown to do, which population was studied, and how closely the commercial product matches the research .

Favorable findings were reviewed alongside missed primary endpoints, null studies, adverse events, withdrawals, formulation differences, funding disclosures, and gaps in long-term evidence.

This is a structured evidence review rather than a formal systematic review or meta-analysis. The ratings are intended to help readers interpret the type and maturity of the evidence, not replace individualized medical advice.

Research process

How each ingredient was evaluated

Every ingredient was examined using the same core questions so that biochemical importance, marketing language, biomarker changes, and practical human outcomes were not treated as equivalent evidence.

Match the exact intervention

The review distinguishes the compound, stereoisomer, salt, extract, formulation, dose, and duration . Evidence from cocoa, a botanical mixture, another stereoisomer, or a substantially different dose was not treated as automatically transferable.

Prioritize primary human research

Full-text randomized trials, controlled human studies, pharmacokinetic studies, muscle-biopsy studies, and direct physiological measurements were prioritized. Cell and animal findings were used to explain mechanisms, not to establish a human clinical outcome.

Separate direct from indirect evidence

Direct mitochondrial respiration, tissue measurements, enzyme activity, mitochondrial structure, ATP-related outcomes, and physical function were distinguished from blood biomarkers, pathway markers, antioxidant measurements, and mechanistic inference.

Record positive and null findings

A positive secondary or exploratory outcome was not allowed to obscure a missed primary endpoint. Null results, inconsistent findings, adverse events, withdrawals, and unsuccessful trials were retained in the evidence assessment.

Evaluate the population studied

Evidence from nutritional deficiency, genetic mitochondrial disease, heart failure, sarcopenia, diabetes, or another clinical population was not generalized to healthy adults without qualification.

Compare the research dose

The dose used in the study was compared with the amount provided by typical commercial servings. Products using substantially lower amounts were not assumed to reproduce outcomes observed at a higher research dose.

Review safety by duration

Short-term tolerance was not described as proof of long-term safety. Known medication interactions, dose-related effects, organ-specific safety signals, and uncertainty about prolonged use were included where relevant.

Review funding and conflicts

Product supply, sponsor involvement, employee authorship, intellectual-property interests, and concentration of evidence within one research group were considered when judging confidence and the need for independent replication.

Evidence-rating system

Ratings apply to the specific mitochondrial claim

An ingredient can have strong evidence for one defined use and limited evidence for another. The rating therefore reflects the exact mitochondrial, muscle, metabolic, or functional claim being discussed.

Strong for a specific use

Replicated human evidence supports a defined outcome

Multiple relevant human studies support a clear function or clinical use. The evidence may still be narrow and should not be converted into a broader claim of universal mitochondrial improvement.

Moderate or context-specific

Human evidence exists but depends on context

Findings may depend on deficiency, disease, age, baseline status, formulation, dose, study duration, or the specific outcome measured.

Early or mixed

Promising findings require broader confirmation

Human evidence may include small trials, tissue-level findings, favorable secondary outcomes, inconsistent results, or limited independent replication.

Limited or primarily preclinical

Human mitochondrial evidence is sparse or indirect

The claim relies mainly on cell research, animal models, mechanistic reasoning, indirect biomarkers, uncontrolled studies, or evidence from a different compound or formulation.

Pricing method

Approximate cost at the labeled daily serving

Price ranges are intended to show the practical difference between ingredient categories, not identify the lowest-priced retailer or recommend a specific competing brand.

Prices reflect regular U.S. retail pricing reviewed agosto 5, 2026.
Promotional discounts, subscriptions, coupons, tax, and shipping were excluded.
The monthly calculation generally uses the manufacturer’s labeled daily serving.
Where research doses substantially exceed typical label servings, the likely research-matched cost is noted separately.
Different chemical forms, delivery systems, and purity standards can produce large differences in price and should not be assumed to be equivalent.

Review limitations

What this comparison can and cannot establish

The page is designed to improve evidence interpretation, but it cannot eliminate the limitations of the underlying research.

Not a meta-analysis

Results were not statistically pooled

Differences in dose, population, product form, trial duration, and outcome measurement often make simple numerical pooling inappropriate.

Uneven evidence bases

Research volume differs substantially

Creatine and CoQ10 have much larger human literatures than newer ingredients. A larger literature can also reveal more null findings and limitations.

Product variation

Ingredient names do not guarantee equivalence

Purity, stereochemistry, salt, extraction method, formulation, stability, contaminants, dose, and bioavailability can vary between products using the same general ingredient name.

Small and short trials

Long-term outcomes remain uncertain

Many studies include fewer than 100 participants and last only several weeks or months. These designs cannot establish long-term effectiveness, safety, or disease prevention.

Publication and sponsor effects

The published literature may be incomplete

Positive results may be more likely to be published. Several supplement research programs also involve manufacturer funding, supplied products, patents, or investigator commercial interests.

Evidence continues to change

Ratings are not permanent

New trials may strengthen, narrow, or contradict the conclusions presented here. Research dates are provided so the page can be reviewed and updated.

Selected research library

Primary studies and authoritative sources

The links below represent the principal studies and reviews used to evaluate the claims presented on this page. They are grouped by supplement category for easier review.

Purified (−)-epicatechin, muscle, and redox research 8 sources

(−)-epicatequina
Human pharmacokinetic study of purified (−)-epicatechin
Examines absorption, metabolism, and circulating epicatechin-derived metabolites after oral administration.
(−)-epicatequina
Human handgrip-strength and follistatin-to-myostatin study
Short human proof-of-concept study evaluating strength and muscle-growth signaling after purified compound use.
(−)-epicatequina
Sarcopenia trial examining muscle mass, mobility, and training outcomes
Controlled human research involving older men with sarcopenia and resistance-training groups.
(−)-epicatequina
Becker muscular dystrophy muscle-biopsy study
Reports mitochondrial structural, signaling, biogenesis-related, and muscle findings after eight weeks.
(−)-epicatequina
Human and translational mitochondrial and muscle research
Examines mitochondrial enzymes, muscle signaling, and related physiological pathways.
(−)-epicatequina
(−)-Epicatechin modulates mitochondrial redox in vascular cell models of oxidative stress
Human endothelial-cell experiments examining mitochondrial superoxide and redox responses under high-glucose and respiratory-chain stress conditions.
(−)-epicatequina
(−)-Epicatechin improves mitochondrial-related proteins and oxidative-stress measures in dystrophic mouse muscle
Preclinical study reporting changes in glutathione redox balance, SOD2, catalase, thioredoxin, glutathione peroxidase, citrate synthase activity, and mitochondrial-related proteins.
(−)-epicatequina
Recovery of mitochondrial-biogenesis and oxidative-stress indicators with (−)-epicatechin in senile mice
Preclinical aging study examining glutathione redox balance, endogenous antioxidant enzymes, oxidative damage, and mitochondrial biogenesis-related markers across several tissues.

Polyphenols and signaling compounds 17 sources

EGCG
Controlled human exercise and metabolic study
Representative human evidence used to evaluate performance and metabolic claims.
EGCG
Large randomized green-tea-extract safety trial
Important for evaluating liver-enzyme abnormalities and high-dose concentrated-extract safety.
Resveratrol
Human metabolic and skeletal-muscle study
Representative favorable human research involving metabolic and mitochondrial-related outcomes.
Resveratrol
Controlled trial with null skeletal-muscle findings
Included to preserve evidence that did not support improved muscle mitochondrial function.
Resveratrol
Human exercise-adaptation and metabolic evidence
Examines whether supplementation adds to or interferes with expected exercise-related adaptation.
Quercetina
Human resistance-training and strength study
Representative recent functional research involving quercetin supplementation and exercise training.
Quercetina
Controlled human exercise study
Used to assess inconsistent exercise and performance findings.
Apple procyanidins
Human apple-polyphenol study
Examines metabolic or body-composition outcomes from an apple polyphenol intervention.
Apple procyanidins
Mixed grape-and-apple polyphenol exercise study
Illustrates why results from a multi-ingredient polyphenol product cannot be attributed to apple procyanidins alone.
Curcumina
Human curcumin exercise and recovery research
Representative formulation-specific study involving inflammatory, recovery, or physical outcomes.
Curcumina
Controlled human curcumin study
Used to assess indirect functional and inflammatory outcomes.
Curcumina
Curcumin bioavailability and formulation research
Supports the distinction between native curcumin and enhanced-delivery formulations.
DHM
Human dihydromyricetin combination-product trial
Includes liver and metabolic outcomes and a missed primary endpoint.
Genisteína
Long-duration human genistein clinical trial
Representative evidence for bone and menopausal outcomes rather than direct mitochondrial improvement.
Genisteína
Long-term genistein efficacy and safety research
Used to assess extended exposure, clinical outcomes, and hormone-related considerations.
PQQ
Controlled exercise study of PQQ
Reported a pathway-marker signal without improved performance or body composition.
PQQ
Exploratory human PQQ study
Representative early human biomarker research.
PQQ
Recent PQQ-containing cognition study
Included with the limitation that combination-product cognition findings do not directly establish a mitochondrial effect from isolated PQQ.

NAD+ precursors 6 sources

NMN
Randomized human NMN trial
Evaluates NAD-related biomarkers and selected metabolic or functional outcomes.
NMN
Controlled NMN physical-function study
Used to distinguish primary outcomes from secondary gait, sleep, or exploratory findings.
NMN
2026 human NAD-precursor comparative research
Recent evidence used to evaluate tissue-specific NAD responses and functional interpretation.
NR
Direct skeletal-muscle NR study
Measures muscle NAD-related metabolites and mitochondrial respiration or bioenergetics.
NR
Controlled human NR metabolic study
Evaluates NAD-related biomarker changes alongside functional and metabolic outcomes.
NMN and NR
Comparative evidence on NAD elevation and tissue response
Supports the distinction between circulating NAD-related biomarkers and direct mitochondrial or functional outcomes.

Mitophagy and mitochondrial quality control 5 sources

Urolitina A
Randomized human urolithin A trial
Evaluates muscle endurance, strength, mitochondrial biomarkers, and primary functional endpoints.
Urolitina A
Controlled urolithin A muscle and mitochondrial study
Includes selected positive outcomes together with null primary or direct mitochondrial findings.
(−)-epicatequina
Human mitochondrial structure and biogenesis-related evidence
Provides human tissue context for the broader mitochondrial renewal profile of purified (−)-epicatechin.
(−)-epicatequina
Induction of mitophagy by green tea extracts and tea polyphenols
Laboratory study showing that isolated (−)-epicatechin induced mitophagy in normal human fibroblast cells. This is cellular evidence, not a human supplementation trial.
Controle de qualidade
Human GlyNAC trial including mitophagy-related markers
Illustrates the use of pathway markers, fuel oxidation, and physical outcomes in evaluating mitochondrial quality control.

Electron transport and metabolic cofactors 12 sources

CoQ10
Controlled CoQ10 skeletal-muscle study
Evaluates muscle CoQ10, mitochondrial respiration, and physical or metabolic outcomes.
CoQ10
CoQ10 trial involving statin-associated muscle symptoms
Included to evaluate symptom findings and the relationship between circulating and tissue CoQ10.
CoQ10
Controlled CoQ10 muscle and performance study
Representative evidence used to assess inconsistent functional findings.
Alpha-lipoic acid
Four-year NATHAN 1 randomized trial
Missed its primary composite endpoint while reporting selected neuropathy-subscore improvements.
Alpha-lipoic acid
Systematic review of alpha-lipoic acid for diabetic neuropathy
Reviews efficacy, attrition, adverse-event reporting, and certainty limitations.
L-carnitine
Randomized metabolic-flexibility trial
Examines skeletal-muscle acetylcarnitine formation and fuel flexibility in participants with impaired glucose tolerance.
L-carnitine
Mitochondrial-myopathy exercise trial
Disease-specific crossover study evaluating exercise performance after L-carnitine supplementation.
L-carnitine
Large randomized cancer-fatigue trial
Increased circulating carnitine without improving the primary fatigue outcome compared with placebo.
Riboflavin
Riboflavin deficiency and inborn errors of metabolism review
Explains the roles of FMN and FAD and the clinical importance of riboflavin-responsive disorders.
Riboflavin
Mitochondrial Medicine Society consensus statement
Provides clinical recommendations for riboflavin, CoQ10, alpha-lipoic acid, and carnitine in mitochondrial disease.
Riboflavin
Clinical review of mitochondrial-disease therapies
Discusses riboflavin-responsive disorders and limitations of broader mitochondrial supplementation evidence.
Cofactors
Review of nutritional approaches in mitochondrial health and disease
Provides biochemical context for carnitine, CoQ10, alpha-lipoic acid, riboflavin, and related compounds.

Energy buffering, substrate, taurine, and GlyNAC 13 sources

Creatine
International Society of Sports Nutrition creatine position stand
Reviews creatine monohydrate, muscle uptake, strength, power, lean mass, dosing, and safety.
D-ribose
Randomized D-ribose and ubiquinol heart-failure trial
Reported ATP-related changes without improvement in the six-minute walk outcome.
D-ribose
Human exercise-performance and recovery study
Evaluates 10 grams per day during a multiday exercise protocol.
D-ribose
Double-blind crossover trial in McArdle disease
Illustrates condition-specific evidence and the use of a high daily research dose.
Taurine
Taurine deficiency as a driver of aging
Major preclinical and observational study that proposed a taurine-aging model and called for human clinical trials.
Taurine
Experimental evidence against taurine deficiency as a driver of aging in humans
Study of 137 physically active and inactive men aged 20 to 93. Circulating taurine was not associated with age, muscle mass, strength, physical performance, or skeletal-muscle mitochondrial function.
Taurine
Human adipose-tissue mitochondrial study
Randomized study examining taurine, exercise, mitochondrial respiration, and fatty-acid oxidation in women with obesity.
Taurine
Heart-failure exercise-capacity trial
Small randomized study reporting improved exercise time, distance, and metabolic equivalents.
Taurine
Exercise-induced muscle-damage recovery study
Controlled crossover study with selected recovery findings and several null outcomes.
GlyNAC
Randomized GlyNAC trial in older adults
Evaluates glutathione, oxidative stress, mitochondrial fuel oxidation, molecular markers, physical function, and strength.
GlyNAC
Open-label GlyNAC pilot trial
Reports changes in glutathione, fuel oxidation, strength, gait speed, cognition, and other aging-related outcomes.
GlyNAC
Randomized dose-ranging study in healthy older adults
Did not improve the primary circulating glutathione endpoint across the full cohort and identified possible responder subgroups.
GlyNAC
Controlled GlyNAC redox-status trial
Important null and subgroup evidence used to balance the smaller favorable trials.

Disclosure and medical notice

Transparency matters in a commercial comparison

This page is published by FMG Health Sciences, the company that markets Mitozz. Mitozz is therefore the only named commercial product in the comparison. Other entries are compared as ingredient categories rather than selected competing brands.

The research process was designed to retain favorable, mixed, null, and safety findings and to apply the same evidence questions across all ingredient categories.

Commercial involvement does not eliminate potential bias. Readers are encouraged to review the linked studies directly and consider study design, population, dose, product form, funding, and conflicts of interest.

Educational information, not medical advice

Supplements can affect medical conditions, laboratory results, surgery, pregnancy, blood pressure, blood glucose, anticoagulation, and medication response. Discuss supplement use with a qualified healthcare professional, especially when managing a medical condition or taking prescription medication.